Glia and alpha-synuclein in neurodegeneration: A complex interaction

Neurobiology of Disease

Volumn 85, Issue , 2016, Pages 262-274

  Brück, Dominik ^a   Wenning, Gregor K ^a   Stefanova, Nadia ^a   Fellner, Lisa ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Astroglia; Dementia with Lewy bodies; Glial cytoplasmic inclusions; Lewy bodies; Microglia; Multiple system atrophy; Oligodendroglia; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; CXCL1 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

CELL ACTIVATION; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CYTOKINE RELEASE; DIFFUSE LEWY BODY DISEASE; DOWN REGULATION; GLIA CELL; HUMAN; MACROGLIA; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SHY DRAGER SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; ANIMAL; DEGENERATIVE DISEASE; GLIA; METABOLISM; NERVE DEGENERATION;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROGLIA;

EID: 84949725441     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.003     Document Type: Review

References (223)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25(1):239-252.
2. Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 2012, 33(2). (430 e431-433).
3. Ahmed Z., Asi Y.T., Sailer A., Lees A.J., Houlden H., Revesz T., Holton J.L. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol. 2012, 38(1):4-24.
4. Al-Chalabi A., Durr A., Wood N.W., Parkinson M.H., Camuzat A., Hulot J.S., Morrison K.E., Renton A., Sussmuth S.D., Landwehrmeyer B.G., Ludolph A., Agid Y., Brice A., Leigh P.N., Bensimon G., Group, N.G.S. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 2009, 4(9):e7114.
5. Alvarez-Erviti L., Couch Y., Richardson J., Cooper J.M., Wood M.J. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci. Res. 2011, 69(4):337-342.
6. Arai T., Ueda K., Ikeda K., Akiyama H., Haga C., Kondo H., Kuroki N., Niizato K., Iritani S., Tsuchiya K. Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein. Neurosci. Lett. 1999, 259(2):83-86.
7. Arima K., Ueda K., Sunohara N., Arakawa K., Hirai S., Nakamura M., Tonozuka-Uehara H., Kawai M. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. 1998, 96(5):439-444.
8. Asi Y.T., Simpson J.E., Heath P.R., Wharton S.B., Lees A.J., Revesz T., Houlden H., Holton J.L. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 2014, 62(6):964-970.
9. Auluck P.K., Caraveo G., Lindquist S. Alpha-synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 2010, 26:211-233.
10. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152(4):879-884.
11. Balasingam V., Dickson K., Brade A., Yong V.W. Astrocyte reactivity in neonatal mice: apparent dependence on the presence of reactive microglia/macrophages. Glia 1996, 18(1):11-26.
12. Barcia C., Ros C.M., Annese V., Gomez A., Ros-Bernal F., Aguado-Yera D., Martinez-Pagan M.E., de Pablos V., Fernandez-Villalba E., Herrero M.T. IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis. 2011, 2:e142.
13. Beyer K., Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J. Neuropathol. Exp. Neurol. 2007, 66(11):965-974.
14. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299(5604):256-259.
15. Boudes M., Uvin P., Pinto S., Voets T., Fowler C.J., Wenning G.K., De Ridder D., Stefanova N. Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov. Disord. 2013, 28(3):347-355.
16. Braak H., Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol. Aging 2004, 25(1):19-23.
17. Braak H., Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv. Anat. Embryol. Cell Biol. 2009, 201:1-119.
18. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 2002, 249(Suppl. 3). (III/1-5).
19. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24(2):197-211.
20. Braak H., Rub U., Gai W.P., Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 2003, 110(5):517-536.
21. Braak H., Sastre M., Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol. 2007, 114(3):231-241.
22. Braidy N., Gai W.P., Xu Y.H., Sachdev P., Guillemin G.J., Jiang X.M., Ballard J.W., Horan M.P., Fang Z.M., Chong B.H., Chan D.K. Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl. Neurodegener 2013, 2(1):20.
23. Brudek T., Winge K., Agander T.K., Pakkenberg B. Screening of Toll-like receptors expression in multiple system atrophy brains. Neurochem. Res. 2013, 38(6):1252-1259.
24. Burke R.E., Dauer W.T., Vonsattel J.P. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann. Neurol. 2008, 64(5):485-491.
25. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., Orrison B., Chen A., Ellis C.E., Paylor R., Lu B., Nussbaum R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22(20):8797-8807.
26. Calne D.B., Snow B.J., Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 1992, 32(Suppl.):S125-S127.
27. Cao S., Theodore S., Standaert D.G. Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol. Neurodegener. 2010, 5:42.
28. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123(3):383-396.
29. Choi D.K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.C., Jackson-Lewis V., Vila M., Vonsattel J.P., Heinecke J.W., Przedborski S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 2005, 25(28):6594-6600.
30. Constantinescu R., Rosengren L., Johnels B., Zetterberg H., Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat. Disord. 2010, 16(2):142-145.
31. Damier P., Hirsch E.C., Zhang P., Agid Y., Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993, 52(1):1-6.
32. de Pablos R.M., Herrera A.J., Espinosa-Oliva A.M., Sarmiento M., Munoz M.F., Machado A., Venero J.L. Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation. J. Neuroinflammation 2014, 11:34.
33. Dean J.M., Wang X., Kaindl A.M., Gressens P., Fleiss B., Hagberg H., Mallard C. Microglial MyD88 signaling regulates acute neuronal toxicity of LPS-stimulated microglia in vitro. Brain Behav. Immun. 2010, 24(5):776-783.
34. del Rio-Hortega P. Microglia. Cytology and Cellular Pathology of the Nervous System 1932, W. Penfield, New York, Hoeber, (PB: 483-534).
35. Deshpande M., Zheng J., Borgmann K., Persidsky R., Wu L., Schellpeper C., Ghorpade A. Role of activated astrocytes in neuronal damage: potential links to HIV-1-associated dementia. Neurotox. Res. 2005, 7(3):183-192.
36. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(31):13010-13015.
37. Dev K.K., Hofele K., Barbieri S., Buchman V.L., van der Putten H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003, 45(1):14-44.
38. Dickson D.W., Lin W., Liu W.K., Yen S.H. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999, 9(4):721-732.
39. Doorn K.J., Moors T., Drukarch B., van de Berg W., Lucassen P.J., van Dam A.M. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Acta Neuropathol. Commun. 2014, 2:90.
40. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68(5):384-386.
41. Ebrahimi-Fakhari D., Cantuti-Castelvetri I., Fan Z., Rockenstein E., Masliah E., Hyman B.T., McLean P.J., Unni V.K. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 2011, 31(41):14508-14520.
42. Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., Wang L., Zuchner S., Konidari I., Wang G., Singer C., Nahab F., Scott B., Stajich J.M., Pericak-Vance M., Haines J., Vance J.M., Martin E.R. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 2010, 74(2):97-109.
43. El-Agnaf O.M., Curran M.D., Wallace A., Middleton D., Murgatroyd C., Curtis A., Perry R., Jaros E. Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies cases. Neuroreport 1998, 9(17):3925-3927.
44. Elbaz A., Ross O.A., Ioannidis J.P., Soto-Ortolaza A.I., Moisan F., Aasly J., Annesi G., Bozi M., Brighina L., Chartier-Harlin M.C., Destee A., Ferrarese C., Ferraris A., Gibson J.M., Gispert S., Hadjigeorgiou G.M., Jasinska-Myga B., Klein C., Kruger R., Lambert J.C., Lohmann K., van de Loo S., Loriot M.A., Lynch T., Mellick G.D., Mutez E., Nilsson C., Opala G., Puschmann A., Quattrone A., Sharma M., Silburn P.A., Stefanis L., Uitti R.J., Valente E.M., Vilarino-Guell C., Wirdefeldt K., Wszolek Z.K., Xiromerisiou G., Maraganore D.M., Farrer M.J., Genetic Epidemiology of Parkinson's Disease, C Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann. Neurol. 2011, 69(5):778-792.
45. Emmanouilidou E., Melachroinou K., Roumeliotis T., Garbis S.D., Ntzouni M., Margaritis L.H., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30(20):6838-6851.
46. Eriksen J.L., Dawson T.M., Dickson D.W., Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 2003, 40(3):453-456.
47. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
48. Fellner L., Stefanova N. The role of glia in alpha-synucleinopathies. Mol. Neurobiol. 2013, 47(2):575-586.
49. Fellner L., Jellinger K.A., Wenning G.K., Stefanova N. Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol. 2011, 121(6):675-693.
50. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., Wenning G.K., Stefanova N. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013, 61(3):349-360.
51. Fellner L., Wenning G.K., Stefanova N. Models of multiple system atrophy. Curr. Top. Behav. Neurosci. 2013.
52. Foulds P.G., Mitchell J.D., Parker A., Turner R., Green G., Diggle P., Hasegawa M., Taylor M., Mann D., Allsop D. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 2011, 25(12):4127-4137.
53. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4(2):160-164.
54. Gao L., Tang H., Nie K., Wang L., Zhao J., Gan R., Huang J., Zhu R., Feng S., Duan Z., Zhang Y., Wang L. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int. J. Neurosci. 2014.
55. 11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003, 61(5):686-689.
56. 11C](R)-PK11195 PET in progressive supranuclear palsy. Mov. Disord. 2006, 21(1):89-93.
57. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290(5493):985-989.
58. Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., Kaufmann H., Klockgether T., Lang A.E., Lantos P.L., Litvan I., Mathias C.J., Oliver E., Robertson D., Schatz I., Wenning G.K. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 1999, 163(1):94-98.
59. Gitler A.D., Shorter J. Prime time for alpha-synuclein. J. Neurosci. 2007, 27(10):2433-2434.
60. Goedert M. Parkinson's disease and other alpha-synucleinopathies. Clin. Chem. Lab. Med. 2001, 39(4):308-312.
61. Goker-Alpan O., Giasson B.I., Eblan M.J., Nguyen J., Hurtig H.I., Lee V.M., Trojanowski J.Q., Sidransky E. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006, 67(5):908-910.
62. Grosso H., Woo J.M., Lee K.W., Im J.Y., Masliah E., Junn E., Mouradian M.M. Transglutaminase 2 exacerbates alpha-synuclein toxicity in mice and yeast. FASEB J. 2014, 28(10):4280-4291.
63. Gu X.L., Long C.X., Sun L., Xie C., Lin X., Cai H. Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol. Brain 2010, 3:12.
64. Halliday G.M., Stevens C.H. Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 2011, 26(1):6-17.
65. Hamza T.H., Zabetian C.P., Tenesa A., Laederach A., Montimurro J., Yearout D., Kay D.M., Doheny K.F., Paschall J., Pugh E., Kusel V.I., Collura R., Roberts J., Griffith A., Samii A., Scott W.K., Nutt J., Factor S.A., Payami H. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42(9):781-785.
66. Hanisch U.K. Microglia as a source and target of cytokines. Glia 2002, 40(2):140-155.
67. Hansen C., Angot E., Bergstrom A.L., Steiner J.A., Pieri L., Paul G., Outeiro T.F., Melki R., Kallunki P., Fog K., Li J.Y., Brundin P. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121(2):715-725.
68. Harms A.S., Cao S., Rowse A.L., Thome A.D., Li X., Mangieri L.R., Cron R.Q., Shacka J.J., Raman C., Standaert D.G. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 2013, 33(23):9592-9600.
69. Hasegawa T., Matsuzaki M., Takeda A., Kikuchi A., Akita H., Perry G., Smith M.A., Itoyama Y. Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res. 2004, 1013(1):51-59.
70. Hashioka S., Klegeris A., Schwab C., McGeer P.L. Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol. Aging 2009, 30(12):1924-1935.
71. Hashioka S., Klegeris A., Schwab C., Yu S., McGeer P.L. Differential expression of interferon-gamma receptor on human glial cells in vivo and in vitro. J. Neuroimmunol. 2010, 225(1-2):91-99.
72. Hauser D.N., Cookson M.R. Astrocytes in Parkinson's disease and DJ-1. J. Neurochem. 2011, 117(3):357-358.
73. Henchcliffe C., Dodel R., Beal M.F. Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Prog. Neurobiol. 2011, 95(4):601-613.
74. Hirsch E.C., Hunot S., Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S9-S15.
75. Iannaccone S., Cerami C., Alessio M., Garibotto V., Panzacchi A., Olivieri S., Gelsomino G., Moresco R.M., Perani D. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat. Disord. 2013, 19(1):47-52.
76. Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364(9440):1169-1171.
77. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106(6):518-526.
78. Ishizawa K., Komori T., Sasaki S., Arai N., Mizutani T., Hirose T. Microglial activation parallels system degeneration in multiple system atrophy. J. Neuropathol. Exp. Neurol. 2004, 63(1):43-52.
79. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14(2):467-475.
80. Iwata A., Riley B.E., Johnston J.A., Kopito R.R. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 2005, 280(48):40282-40292.
81. Jecmenica-Lukic M., Poewe W., Tolosa E., Wenning G.K. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol. 2012, 11(4):361-368.
82. Jellinger K.A. Neuropathological spectrum of synucleinopathies. Mov. Disord. 2003, 18(Suppl. 6):S2-S12.
83. Jellinger K.A. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 2009, 1792(7):730-740.
84. Jellinger K.A., Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?. Acta Neuropathol. 2006, 112(3):253-260.
85. Jellinger K.A., Lantos P.L. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol. 2010, 119(6):657-667.
86. Jellinger K.A., Seppi K., Wenning G.K. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov. Disord. 2005, 20(Suppl. 12):S29-S36.
87. Jeon B.S., Farrer M.J., Bortnick S.F., Korean Canadian Alliance on Parkinson's, D., Related, D Mutant COQ2 in multiple-system atrophy. N. Engl. J. Med. 2014, 371(1):80.
88. Jurewicz A., Matysiak M., Tybor K., Kilianek L., Raine C.S., Selmaj K. Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 2005, 128(Pt 11):2675-2688.
89. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Spooren W., Fuss B., Mallon B., Macklin W.B., Fujiwara H., Hasegawa M., Iwatsubo T., Kretzschmar H.A., Haass C. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 2002, 3(6):583-588.
90. Kato S., Nakamura H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol. 1990, 79(6):584-594.
91. Kato S., Nakamura H., Hirano A., Ito H., Llena J.F., Yen S.H. Argyrophilic ubiquitinated cytoplasmic inclusions of Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol. 1991, 82(6):488-493.
92. Katsuse O., Iseki E., Kosaka K. Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. Neuropathology 2003, 23(1):9-15.
93. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115(6):727-738.
94. Kim C., Ho D.H., Suk J.E., You S., Michael S., Kang J., Joong Lee S., Masliah E., Hwang D., Lee H.J., Lee S.J. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013, 4:1562.
95. Kisos H., Pukass K., Ben-Hur T., Richter-Landsberg C., Sharon R. Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies. PLoS ONE 2012, 7(10):e46817.
96. Klegeris A., Giasson B.I., Zhang H., Maguire J., Pelech S., McGeer P.L. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J. 2006, 20(12):2000-2008.
97. Klegeris A., Pelech S., Giasson B.I., Maguire J., Zhang H., McGeer E.G., McGeer P.L. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 2008, 29(5):739-752.
98. Knott C., Stern G., Kingsbury A., Welcher A.A., Wilkin G.P. Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra. Parkinsonism Relat. Disord. 2002, 8(5):329-341.
99. Kollensperger M., Geser F., Seppi K., Stampfer-Kountchev M., Sawires M., Scherfler C., Boesch S., Mueller J., Koukouni V., Quinn N., Pellecchia M.T., Barone P., Schimke N., Dodel R., Oertel W., Dupont E., Ostergaard K., Daniels C., Deuschl G., Gurevich T., Giladi N., Coelho M., Sampaio C., Nilsson C., Widner H., Sorbo F.D., Albanese A., Cardozo A., Tolosa E., Abele M., Klockgether T., Kamm C., Gasser T., Djaldetti R., Colosimo C., Meco G., Schrag A., Poewe W., Wenning G.K., European, M.S.A.S.G. Red flags for multiple system atrophy. Mov. Disord. 2008, 23(8):1093-1099.
100. Konno M., Hasegawa T., Baba T., Miura E., Sugeno N., Kikuchi A., Fiesel F.C., Sasaki T., Aoki M., Itoyama Y., Takeda A. Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol. Neurodegener. 2012, 7:38.
101. Kragh C.L., Lund L.B., Febbraro F., Hansen H.D., Gai W.P., El-Agnaf O., Richter-Landsberg C., Jensen P.H. Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J. Biol. Chem. 2009, 284(15):10211-10222.
102. Kragh C.L., Fillon G., Gysbers A., Hansen H.D., Neumann M., Richter-Landsberg C., Haass C., Zalc B., Lubetzki C., Gai W.P., Halliday G.M., Kahle P.J., Jensen P.H. FAS-dependent cell death in alpha-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS ONE 2013, 8(1):e55243.
103. Kuzdas D., Stemberger S., Gaburro S., Stefanova N., Singewald N., Wenning G.K. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. Exp. Neurol. 2013, 247:531-536.
104. Kuzdas-Wood D., Stefanova N., Jellinger K.A., Seppi K., Schlossmacher M.G., Poewe W., Wenning G.K. Towards translational therapies for multiple system atrophy. Prog. Neurobiol. 2014, 118:19-35.
105. Lee H.J., Suk J.E., Bae E.J., Lee J.H., Paik S.R., Lee S.J. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int. J. Biochem. Cell Biol. 2008, 40(9):1835-1849.
106. Lee M., Schwab C., Yu S., McGeer E., McGeer P.L. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol. Aging 2009, 30(10):1523-1534.
107. Lee H.J., Suk J.E., Patrick C., Bae E.J., Cho J.H., Rho S., Hwang D., Masliah E., Lee S.J. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 2010, 285(12):9262-9272.
108. Liberto C.M., Albrecht P.J., Herx L.M., Yong V.W., Levison S.W. Pro-regenerative properties of cytokine-activated astrocytes. J. Neurochem. 2004, 89(5):1092-1100.
109. Lindersson E., Lundvig D., Petersen C., Madsen P., Nyengaard J.R., Hojrup P., Moos T., Otzen D., Gai W.P., Blumbergs P.C., Jensen P.H. p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 2005, 280(7):5703-5715.
110. Luk K.C., Song C., O'Brien P., Stieber A., Branch J.R., Brunden K.R., Trojanowski J.Q., Lee V.M. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(47):20051-20056.
111. Mackenzie I.R. Activated microglia in dementia with Lewy bodies. Neurology 2000, 55(1):132-134.
112. Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., Mann D.M., Hasegawa M. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013, 136(Pt 4):1128-1138.
113. McKeith I. Dementia with Lewy bodies. Dialogues Clin. Neurosci. 2004, 6(3):333-341.
114. Miki Y., Mori F., Tanji K., Kakita A., Takahashi H., Wakabayashi K. Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. Neuropathology 2011, 31(6):561-568.
115. Miller D.W., Johnson J.M., Solano S.M., Hollingsworth Z.R., Standaert D.G., Young A.B. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural Transm. 2005, 112(12):1613-1624.
116. Mirza B., Hadberg H., Thomsen P., Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000, 95(2):425-432.
117. Mizuno T., Kuno R., Nitta A., Nabeshima T., Zhang G., Kawanokuchi J., Wang J., Jin S., Takeuchi H., Suzumura A. Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes. Brain Res. 2005, 1066(1-2):78-85.
118. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T.F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H.A., McLean P.J., Trenkwalder C., Sarracino D.A., Vonsattel J.P., Locascio J.J., El-Agnaf O.M., Schlossmacher M.G. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 2008, 213(2):315-325.
119. Mollenhauer B., Esselmann H., Roeber S., Schulz-Schaeffer W.J., Trenkwalder C., Bibl M., Steinacker P., Kretzschmar H.A., Wiltfang J., Otto M. Different CSF beta-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J. Neural Transm. 2011, 118(5):691-697.
120. Multiple-System Atrophy Research, C Mutations in COQ2 in familial and sporadic multiple-system atrophy. N. Engl. J. Med. 2013, 369(3):233-244.
121. Mythri R.B., Venkateshappa C., Harish G., Mahadevan A., Muthane U.B., Yasha T.C., Srinivas Bharath M.M., Shankar S.K. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res. 2011, 36(8):1452-1463.
122. Nagatsu T., Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 2005, 11(8):999-1016.
123. Nakamura S., Kawamoto Y., Nakano S., Akiguchi I. Expression of the endocytosis regulatory proteins Rab5 and Rabaptin-5 in glial cytoplasmic inclusions from brains with multiple system atrophy. Clin. Neuropathol. 2000, 19(2):51-56.
124. Neumann H., Schweigreiter R., Yamashita T., Rosenkranz K., Wekerle H., Barde Y.A. Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. J. Neurosci. 2002, 22(3):854-862.
125. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308(5726):1314-1318.
126. Nishie M., Mori F., Fujiwara H., Hasegawa M., Yoshimoto M., Iwatsubo T., Takahashi H., Wakabayashi K. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 2004, 107(4):292-298.
127. Nishioka K., Hayashi S., Farrer M.J., Singleton A.B., Yoshino H., Imai H., Kitami T., Sato K., Kuroda R., Tomiyama H., Mizoguchi K., Murata M., Toda T., Imoto I., Inazawa J., Mizuno Y., Hattori N. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 2006, 59(2):298-309.
128. Norris E.H., Giasson B.I., Lee V.M. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 2004, 60:17-54.
129. O'Sullivan S.S., Massey L.A., Williams D.R., Silveira-Moriyama L., Kempster P.A., Holton J.L., Revesz T., Lees A.J. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008, 131(Pt 5):1362-1372.
130. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57(2):168-175.
131. Ouchi Y., Yagi S., Yokokura M., Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S200-S204.
132. Ozawa T., Takano H., Onodera O., Kobayashi H., Ikeuchi T., Koide R., Okuizumi K., Shimohata T., Wakabayashi K., Takahashi H., Tsuji S. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci. Lett. 1999, 270(2):110-112.
133. Ozawa T., Okuizumi K., Ikeuchi T., Wakabayashi K., Takahashi H., Tsuji S. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol. 2001, 102(2):188-190.
134. Ozawa T., Paviour D., Quinn N.P., Josephs K.A., Sangha H., Kilford L., Healy D.G., Wood N.W., Lees A.J., Holton J.L., Revesz T. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004, 127(Pt 12):2657-2671.
135. Pan T., Kondo S., Zhu W., Xie W., Jankovic J., Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol. Dis. 2008, 32(1):16-25.
136. Papa M., De Luca C., Petta F., Alberghina L., Cirillo G. Astrocyte-neuron interplay in maladaptive plasticity. Neurosci. Biobehav. Rev. 2014, 42:35-54.
137. Papp M.I., Lantos P.L. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J. Neurol. Sci. 1992, 107(2):172-182.
138. Papp M.I., Lantos P.L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994, 117(Pt 2):235-243.
139. Papp M.I., Kahn J.E., Lantos P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 1989, 94(1-3):79-100.
140. Park J.Y., Paik S.R., Jou I., Park S.M. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease. Glia 2008, 56(11):1215-1223.
141. Parkkinen L., Kauppinen T., Pirttila T., Autere J.M., Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann. Neurol. 2005, 57(1):82-91.
142. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276(5321):2045-2047.
143. Pukass K., Richter-Landsberg C. Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular alpha-synuclein in oligodendrocytes. J. Mol. Neurosci. 2014, 52(3):339-352.
144. Qian L., Flood P.M. Microglial cells and Parkinson's disease. Immunol. Res. 2008, 41(3):155-164.
145. Qian L., Flood P.M., Hong J.S. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J. Neural Transm. 2010, 117(8):971-979.
146. Reyes J.F., Rey N.L., Bousset L., Melki R., Brundin P., Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014, 62(3):387-398.
147. Reynolds A.D., Glanzer J.G., Kadiu I., Ricardo-Dukelow M., Chaudhuri A., Ciborowski P., Cerny R., Gelman B., Thomas M.P., Mosley R.L., Gendelman H.E. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 2008, 104(6):1504-1525.
148. Riedel M., Goldbaum O., Richter-Landsberg C. Alpha-synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. J. Mol. Neurosci. 2009, 39(1-2):226-234.
149. Rohl C., Lucius R., Sievers J. The effect of activated microglia on astrogliosis parameters in astrocyte cultures. Brain Res. 2007, 1129(1):43-52.
150. Rojanathammanee L., Murphy E.J., Combs C.K. Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J. Neuroinflammation 2011, 8:44.
151. Roodveldt C., Labrador-Garrido A., Gonzalez-Rey E., Fernandez-Montesinos R., Caro M., Lachaud C.C., Waudby C.A., Delgado M., Dobson C.M., Pozo D. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants. PLoS ONE 2010, 5(10):e13481.
152. Ros-Bernal F., Hunot S., Herrero M.T., Parnadeau S., Corvol J.C., Lu L., Alvarez-Fischer D., Carrillo-de Sauvage M.A., Saurini F., Coussieu C., Kinugawa K., Prigent A., Hoglinger G., Hamon M., Tronche F., Hirsch E.C., Vyas S. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(16):6632-6637.
153. Saavedra A., Baltazar G., Santos P., Carvalho C.M., Duarte E.P. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol. Dis. 2006, 23(3):533-542.
154. Sacino A.N., Brooks M., Thomas M.A., McKinney A.B., Lee S., Regenhardt R.W., McGarvey N.H., Ayers J.I., Notterpek L., Borchelt D.R., Golde T.E., Giasson B.I. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(29):10732-10737.
155. Sanchez-Guajardo V., Febbraro F., Kirik D., Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS ONE 2010, 5(1):e8784.
156. Sandhu J.K., Gardaneh M., Iwasiow R., Lanthier P., Gangaraju S., Ribecco-Lutkiewicz M., Tremblay R., Kiuchi K., Sikorska M. Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol. Dis. 2009, 33(3):405-414.
157. Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 2006, 116(7):1744-1754.
158. Schmidt S., Linnartz B., Mendritzki S., Sczepan T., Lubbert M., Stichel C.C., Lubbert H. Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria. Hum. Mol. Genet. 2011, 20(6):1197-1211.
159. Scholz S.W., Houlden H., Schulte C., Sharma M., Li A., Berg D., Melchers A., Paudel R., Gibbs J.R., Simon-Sanchez J., Paisan-Ruiz C., Bras J., Ding J., Chen H., Traynor B.J., Arepalli S., Zonozi R.R., Revesz T., Holton J., Wood N., Lees A., Oertel W., Wullner U., Goldwurm S., Pellecchia M.T., Illig T., Riess O., Fernandez H.H., Rodriguez R.L., Okun M.S., Poewe W., Wenning G.K., Hardy J.A., Singleton A.B., Del Sorbo F., Schneider S., Bhatia K.P., Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 2009, 65(5):610-614.
160. Schottlaender L.V., Houlden H., Multiple-System Atrophy Brain Bank, C Mutant COQ2 in multiple-system atrophy. N. Engl. J. Med. 2014, 371(1):81.
161. Schrag A., Ben-Shlomo Y., Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999, 354(9192):1771-1775.
162. Schwarz L., Goldbaum O., Bergmann M., Probst-Cousin S., Richter-Landsberg C. Involvement of macroautophagy in multiple system atrophy and protein aggregate formation in oligodendrocytes. J. Mol. Neurosci. 2012, 47(2):256-266.
163. Sharma M., Wenning G., Kruger R., European Multiple-System Atrophy Study G Mutant COQ2 in multiple-system atrophy. N. Engl. J. Med. 2014, 371(1):80-81.
164. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69(3):570-580.
165. Shults C.W., Rockenstein E., Crews L., Adame A., Mante M., Larrea G., Hashimoto M., Song D., Iwatsubo T., Tsuboi K., Masliah E. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 2005, 25(46):10689-10699.
166. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41(12):1308-1312.
167. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302(5646):841.
168. Song Y.J., Lundvig D.M., Huang Y., Gai W.P., Blumbergs P.C., Hojrup P., Otzen D., Halliday G.M., Jensen P.H. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am. J. Pathol. 2007, 171(4):1291-1303.
169. Song Y.J., Halliday G.M., Holton J.L., Lashley T., O'Sullivan S.S., McCann H., Lees A.J., Ozawa T., Williams D.R., Lockhart P.J., Revesz T.R. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. 2009, 68(10):1073-1083.
170. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 2000, 920:16-27.
171. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 1998, 251(3):205-208.
172. Stefanova N., Klimaschewski L., Poewe W., Wenning G.K., Reindl M. Glial cell death induced by overexpression of alpha-synuclein. J. Neurosci. Res. 2001, 65(5):432-438.
173. Stefanova N., Schanda K., Klimaschewski L., Poewe W., Wenning G.K., Reindl M. Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. J. Neurosci. Res. 2003, 73(3):334-340.
174. Stefanova N., Reindl M., Neumann M., Haass C., Poewe W., Kahle P.J., Wenning G.K. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am. J. Pathol. 2005, 166(3):869-876.
175. Stefanova N., Tison F., Reindl M., Poewe W., Wenning G.K. Animal models of multiple system atrophy. Trends Neurosci. 2005, 28(9):501-506.
176. Stefanova N., Reindl M., Neumann M., Kahle P.J., Poewe W., Wenning G.K. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov. Disord. 2007, 22(15):2196-2203.
177. Stefanova N., Bucke P., Duerr S., Wenning G.K. Multiple system atrophy: an update. Lancet Neurol. 2009, 8(12):1172-1178.
178. Stefanova N., Fellner L., Reindl M., Masliah E., Poewe W., Wenning G.K. Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am. J. Pathol. 2011, 179(2):954-963.
179. Stefanova N., Georgievska B., Eriksson H., Poewe W., Wenning G.K. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox. Res. 2012, 21(4):393-404.
180. Stefanova N., Kaufmann W.A., Humpel C., Poewe W., Wenning G.K. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol. 2012, 124(1):51-65.
181. Stemberger S., Poewe W., Wenning G.K., Stefanova N. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp. Neurol. 2010, 224(2):459-464.
182. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 2008, 29(11):1690-1701.
183. Su X., Federoff H.J., Maguire-Zeiss K.A. Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox. Res. 2009, 16(3):238-254.
184. Tanji K., Mori F., Kakita A., Takahashi H., Wakabayashi K. Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol. Dis. 2011, 43(3):690-697.
185. Tateno F., Sakakibara R., Kawai T., Kishi M., Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2012, 26(3):213-216.
186. Theodore S., Cao S., McLean P.J., Standaert D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2008, 67(12):1149-1158.
187. Thorburne S.K., Juurlink B.H. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J. Neurochem. 1996, 67(3):1014-1022.
188. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., Spillantini M.G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 2003, 278(45):44405-44411.
189. Trotta L., Guella I., Solda G., Sironi F., Tesei S., Canesi M., Pezzoli G., Goldwurm S., Duga S., Asselta R. SNCA and MAPT genes: independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat. Disord. 2012, 18(3):257-262.
190. Tsuboi Y., Dickson D.W. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S47-S51.
191. Tsuboi K., Grzesiak J.J., Bouvet M., Hashimoto M., Masliah E., Shults C.W. Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death. Mol. Cell. Neurosci. 2005, 29(2):259-268.
192. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., Lee V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 1998, 44(3):415-422.
193. Ubhi K., Lee P.H., Adame A., Inglis C., Mante M., Rockenstein E., Stefanova N., Wenning G.K., Masliah E. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. J. Neurosci. Res. 2009, 87(12):2728-2739.
194. Ubhi K., Rockenstein E., Mante M., Inglis C., Adame A., Patrick C., Whitney K., Masliah E. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 2010, 30(18):6236-6246.
195. Ubhi K., Low P., Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci. 2011, 34(11):581-590.
196. Uversky V.N. Alpha-synuclein misfolding and neurodegenerative diseases. Curr. Protein Pept. Sci. 2008, 9(5):507-540.
197. Valera E., Ubhi K., Mante M., Rockenstein E., Masliah E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia 2014, 62(2):317-337.
198. van Rossum D., Hanisch U.K. Microglia. Metab. Brain Dis. 2004, 19(3-4):393-411.
199. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., Tieu K., Przedborski S. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 2001, 14(4):483-489.
200. Vilar M., Chou H.T., Luhrs T., Maji S.K., Riek-Loher D., Verel R., Manning G., Stahlberg H., Riek R. The fold of alpha-synuclein fibrils. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(25):8637-8642.
201. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M., Takahashi H. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 1998, 96(5):445-452.
202. Wakabayashi K., Hayashi S., Yoshimoto M., Kudo H., Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol. 2000, 99(1):14-20.
203. Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D., Srulijes K., Trojanowski J.Q., Lee V.M., Siderowf A.D., Hurtig H., Litvan I., Schiess M.C., Peskind E.R., Masuda M., Hasegawa M., Lin X., Pan C., Galasko D., Goldstein D.S., Jensen P.H., Yang H., Cain K.C., Zhang J. Phosphorylated alpha-synuclein in Parkinson's disease. Sci. Transl. Med. 2012, 4(121). (121ra120).
204. Watanabe H., Saito Y., Terao S., Ando T., Kachi T., Mukai E., Aiba I., Abe Y., Tamakoshi A., Doyu M., Hirayama M., Sobue G. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002, 125(Pt 5):1070-1083.
205. Watts J.C., Giles K., Oehler A., Middleton L., Dexter D.T., Gentleman S.M., DeArmond S.J., Prusiner S.B. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(48):19555-19560.
206. Webster H., Astrom K.E. Gliogenesis: historical perspectives, 1839-1985. Adv. Anat. Embryol. Cell Biol. 2009, 202:1-109.
207. Wenning G.K., Jellinger K.A. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol. 2005, 109(2):129-140.
208. Wenning G., Quinn N. Are Lewy bodies non-specific epiphenomena of nigral damage?. Mov. Disord. 1994, 9(3):378-379.
209. Wenning G.K., Stefanova N. Recent developments in multiple system atrophy. J. Neurol. 2009, 256(11):1791-1808.
210. Wenning G.K., Tison F., Ben Shlomo Y., Daniel S.E., Quinn N.P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 1997, 12(2):133-147.
211. Wenning G.K., Colosimo C., Geser F., Poewe W. Multiple system atrophy. Lancet Neurol. 2004, 3(2):93-103.
212. Wenning G.K., Stefanova N., Jellinger K.A., Poewe W., Schlossmacher M.G. Multiple system atrophy: a primary oligodendrogliopathy. Ann. Neurol. 2008, 64(3):239-246.
213. Wenning G.K., Geser F., Krismer F., Seppi K., Duerr S., Boesch S., Kollensperger M., Goebel G., Pfeiffer K.P., Barone P., Pellecchia M.T., Quinn N.P., Koukouni V., Fowler C.J., Schrag A., Mathias C.J., Giladi N., Gurevich T., Dupont E., Ostergaard K., Nilsson C.F., Widner H., Oertel W., Eggert K.M., Albanese A., del Sorbo F., Tolosa E., Cardozo A., Deuschl G., Hellriegel H., Klockgether T., Dodel R., Sampaio C., Coelho M., Djaldetti R., Melamed E., Gasser T., Kamm C., Meco G., Colosimo C., Rascol O., Meissner W.G., Tison F., Poewe W., European Multiple System Atrophy Study, G. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013, 12(3):264-274.
214. Wennstrom M., Surova Y., Hall S., Nilsson C., Minthon L., Bostrom F., Hansson O., Nielsen H.M. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013, 8(1):e53250.
215. Wilhelmsson U., Bushong E.A., Price D.L., Smarr B.L., Phung V., Terada M., Ellisman M.H., Pekny M. Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(46):17513-17518.
216. Winslow A.R., Chen C.W., Corrochano S., Acevedo-Arozena A., Gordon D.E., Peden A.A., Lichtenberg M., Menzies F.M., Ravikumar B., Imarisio S., Brown S., O'Kane C.J., Rubinsztein D.C. Alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 2010, 190(6):1023-1037.
217. Xilouri M., Stefanis L. Autophagic pathways in Parkinson disease and related disorders. Expert Rev. Mol. Med. 2011, 13:e8.
218. Yamada T., McGeer P.L., McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. 1992, 84(1):100-104.
219. Yazawa I., Giasson B.I., Sasaki R., Zhang B., Joyce S., Uryu K., Trojanowski J.Q., Lee V.M. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005, 45(6):847-859.
220. Yun J.Y., Lee W.W., Lee J.Y., Kim H.J., Park S.S., Jeon B.S. SNCA variants and multiple system atrophy. Ann. Neurol. 2010, 67(4):554-555.
221. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55(2):164-173.
222. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19(6):533-542.
223. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44(4):601-607.